Olink Proteomics

Enabling precision medicine

Company details

Year Aquired

2019

Location

Uppsala, Sweden

Revenue

444

Sector

Life Science

Employees

127

Investment Themes

Changing Demographics

Contact

If you want to know more about Olink Proteomics please contact Tommi Unkuri at: tommi.unkuri@summaequity.com

Olink develops and markets its unique technology for protein analysis in human protein biomarker research. Olink’s proprietary Proximity Extension Assay (PEA) technology enables researchers to analyze large numbers of proteins with high-throughput analysis, exceptional data quality, and minimal sample consumption.

This makes research possible, which previously could not be done, at lower unit costs. The technology drives precision medicine by improving the understanding of the interaction of proteins and human disease, which is key to improve treatment and patient outcomes across many disease areas.

 

Key developments in 2019

Olink has developed rapidly during 2019 and the company has seen very strong traction for its products in the market. The company delivered a 49% revenue growth in the year, driven by strong growth in all geographies, and notably by continued Biopharma adoption of its technology.

Throughout 2019, Olink has expanded its offering into new geographies such as APAC and gained stronger presence within its current footprint. The organization has been strengthened to continue driving strong future growth, and Olink is continuing to relentlessly pursue a number of R&D projects that will further strengthen its offering in the coming years.

Impact Dimensions

The challenges we face

We currently suffer from ineffective medication due to a lack of understanding of the biology of diseases. The shift from "one size fits all" approach to precision medicine is a colossal challenge for science. Delivering the right treatment, to the right patient at the appropriate time requires developing protein biomarker panels to improve our understanding of the human biology and optimize the development of new drugs and treatments.

 

%
of patients receive no benefit from treatment with the top 10 best-selling drugs in the world
%
Share of GDP spent on healthcare in the OECD

 

What is the outcome?

Olink contributes to the understanding of the human biology through its unique technology aimed at science related to proteomics. Olink’s approach enables science that was not previously possible, and is a key contributor to precision medicine.

 

Who are the stakeholders?

Olink's customers are primarily found in pharma and in academic centers, who are focused on drug discovery and understanding biology in human disease. Olink's technology can enable these customers to drive the future of precision medicine, which will greatly benefit individual patients and health systems.

 

How big is the effect, and does it last?

Olink, with a library of over 1,200 validated protein targets, has been mentioned in 343 publications, supporting protein biomarker discovery research globally. The company has hundreds of customers worldwide. Enabling precision medicine is important to drive better patient outcomes and sustainable cost in healthcare systems over time.

 

If Olink didn’t exist…

Since Olink provides a truly unique technology to the market, it makes a great contribution to precision medicine. If Olink did not exist, a vast majority of the research that it enables would not get done.

 

Impact risk: what can go wrong?

Product quality is fundamentally important, so if Olink would be unable to deliver strong product quality, its customers would likely stop using its products.

Year Aquired

2019

Revenue

444

Employees

127

Investment Themes

Changing Demographics

Sector

Life Science

Location

Uppsala, Sweden

Contact

If you want to know more about Olink Proteomics please contact Tommi Unkuri at: tommi.unkuri@summaequity.com

Website

Video

SDG Alignment
SDG Wheel
SDG 3
KPI reporting
SDG 8

REVENUE (SEKm)

2019
+49%
444
2018
298
SDG 3

NO. OF PROTEIN DATA POINTS GENERATED

2019
+71%
151 m
2018
88 m
SDG 3

NO. OF MANUFACTURED KITS

2019
+61%
21,9k
2018
13.6k

NUMBER OF PUBLICATIONS

2019
+55%
343
2018
221

Learn more about Olink

Olink Proteomics AB announce acquisition of Agrisera AB to accelerate production of dedicated antibodies for development of new immunoassays

Dear Friends, UPPSALA, Sweden, May 12, 2020 – Olink today announced the acquisition of Agrisera AB, a Swedish company specializing in polyclonal and monoclonal antibody production. Agrisera offers an extensive collection of primary and secondary antibodies for a broad range of applications, available in various quantities. The acquisition is an important milestone for Olink in its…

Read the story

Summa Equity acquires Olink Proteomics

Summa Equity acquires Olink Proteomics, a Swedish life science company that has developed a unique technology for human biomarker discovery, targeting the global biopharma and academic research and discovery markets. Olink’s purpose is to enable precision medicine through proteomics, thereby contributing to advancing healthcare worldwide. Summa Equity is excited to support this development, and to…

Read the story

Olink Proteomics AB announce acquisition of Agrisera AB to accelerate production of dedicated antibodies for development of new immunoassays

Dear Friends, UPPSALA, Sweden, May 12, 2020 – Olink today announced the acquisition of Agrisera AB, a Swedish company specializing in polyclonal and monoclonal antibody production. Agrisera offers an extensive collection of primary and secondary antibodies for a broad range of applications, available in various quantities. The acquisition is an important milestone for Olink in its...
Learn more

Summa Equity acquires Olink Proteomics

Summa Equity acquires Olink Proteomics, a Swedish life science company that has developed a unique technology for human biomarker discovery, targeting the global biopharma and academic research and discovery markets. Olink’s purpose is to enable precision medicine through proteomics, thereby contributing to advancing healthcare worldwide. Summa Equity is excited to support this development, and to...
Learn more